Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Opioid Use Disorder (OUD)

Ibogaine for Opioid Use Disorder (OUD)

20 papers and 2 clinical trials exploring ibogaine as a treatment for opioid use disorder (oud).

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
IndicationAn estimated 2 million people in the United States have OUD.

Opioid Use Disorder (OUD)

Opioid Use Disorder (OUD) is a prevalent and serious public health issue that is increasingly being targeted for treatment with psychedelics, particularly ibogaine. Recent studies suggest that these compounds may alleviate withdrawal symptoms and reduce cravings, presenting a potential shift in therapeutic approaches to OUD.

Full Opioid Use Disorder (OUD) profile

Academic Research

20 papers
Open Accessindividual

Exploring the Use of Ibogaine in Opioid Recovery: Insights from Lived Experience

This qualitative case study (n=10) explored the experiences of opioid-dependent people in New Zealand who used ibogaine for detoxification. Participants described rapid withdrawal relief, better mood and less anxiety, and some sustained abstinence, but relapse still occurred and preparation, medical screening and post-treatment support were seen as important.

Published
May 22, 2026
Journal
Journal of Psychoactive Drugs
Authors
Walker, J., Deering, D., Unger, B. H.
Open Accessindividual

The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients

This pharmacokinetic study (n=14) on ibogaine (700mg/70kg) for opioid use disorder (OUD) finds significant variability in ibogaine clearance, strongly correlated with CYP2D6 genotype. Ibogaine plasma concentrations correlate with QTc prolongation and cerebellar effects, while neither ibogaine nor noribogaine correlate with the severity of opioid withdrawal symptoms.

Published
March 22, 2024
Journal
Journal of Psychopharmacology
Authors
Knuijver, T., Heine, R. T., Schellekens, A., Heydari, P., Lucas, L., Westra, S., Belgers, M., van Oosteren, T., Verkes, R. J., Kramers, C.
Paywallmeta

Three Decades of Research on the Development of Ibogaine Treatment of Substance Use Disorders: A Scientometric Analysis

This review (2023) examines the interest in ibogaine's therapeutic potential for substance use disorders over three decades (1993-2022). The study identifies a linear growth of publications in the first and third decades, with academic research centers in the United States and Canada being the most productive. Major keywords shifted from cocaine, tobacco, morphine, and alcohol in the first two decades to opioids and psychedelics in the third decade, indicating evolving research trends.

Published
November 6, 2023
Journal
Journal of Psychoactive Drugs
Authors
Fernandes-Nascimento, M. H., Negrão, A. B., Viana-Ferreira, K., Chaves, B. D. R., Yuan-Pang, W.
Open Accessindividual

Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Use

This preprint (2023, v2) animal in vivo and human in vitro study examines a new class of oxa-iboga alkaloids (10 & 40 mg/kg) concerning their effects on opioid addiction in rats and their cardiotoxic effects on human heart cells. In contrast to noribogaine, oxa-iboga analogs exhibited no risk of inducing arrhythmia in adult human primary cardiomyocytes, and oxa-noribogaine induced acute and long-lasting suppression of morphine self-administration in rats in response to both single and repeated dosing regimes.

Published
February 15, 2023
Journal
Biorxiv
Authors
Havel, V., Kruegel, A. C., Bechand, B., Mcintosh, S., Stallings, L., Hodges, A., Wulf, M. G., Nelson, M., Hunkele, A., Ansonoff, M., Pintar, J. E., Hwu, C., Abi-Gerges, N., Zaidi, S. A., Katritch, V., Yang, M., Javitch, J. A., Majumdar, S., Hemby, S. E., Sames, D.
Paywallmeta

A systematic literature review of clinical trials and therapeutic applications of ibogaine

This systematic review (2021) explores clinical trials involving ibogaine and noribogaine. Across the number of trials included, a total of 705 individuals were treated with either ibogaine or noribogaine. It was found that such interventions may be useful for treating substance use disorders, alleviating withdrawal symptoms and cravings. Importantly, a number of severe side effects, including death, that have been recorded in the trials are discussed.

Published
July 1, 2022
Journal
Journal of Substance Abuse Treatment
Authors
Köck, P., Frölich, K., Walter, M., Lang, U., Dürsteler, K. M., Köck, P.
Open Accessindividual

Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study

This open‑label study (n=14) of opioid‑dependent patients given a single 700 mg per 70kg dose of ibogaine‑HCl, treatment produced clinically relevant but reversible cardiac and cerebellar toxicity. The mean maximal QTc(F) prolongation was 95 ms, with 50% of participants exceeding 500 ms, accompanied by bradycardia and severe transient ataxia. Psychomimetic and withdrawal effects were generally manageable, and no torsades de pointes were observed.

Published
August 9, 2021
Journal
Addiction
Authors
Knuijver, T., Schellekens, A., Belgers, M., Donders, R., Kramers, C., Verkes, R. J.

Clinical Trials

2 trials
CompletedPhase II

Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification

This Phase-II RCT (n=20) in Spain randomises methadone-maintained patients to fixed ibogaine (6×100 mg) or ascending ibogaine doses (100→600 mg across six administrations) given when opioid withdrawal appears to support methadone detoxification.

Started
October 28, 2020
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04003948
CompletedPhase II

The Efficacy of Ibogaine in the Treatment of Addiction; an open label, single fixed dose pilot-study of the efficacy of ibogaine in opioid-dependent subjects

This open-label, single-arm Phase II pilot study (n=12) assesses a single fixed oral dose of ibogaine (700mg/70kg) for reducing craving and opioid use in opioid-dependent patients with neuroimaging and electrophysiological secondary measures.

Started
November 10, 2014
Type
interventional
Blinding
none
Randomized
No
Registry ID
2014-000354-11

Explore further

Search all Ibogaine papers Search all Opioid Use Disorder (OUD) trials Full Ibogaine profile Full Opioid Use Disorder (OUD) profile